Allakos Inc. (NASDAQ:ALLK) Shares Sold by Barclays PLC

Barclays PLC reduced its holdings in Allakos Inc. (NASDAQ:ALLK) by 23.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 869,969 shares of the company’s stock after selling 264,049 shares during the quarter. Barclays PLC owned about 0.97% of Allakos worth $568,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Point72 DIFC Ltd purchased a new position in Allakos in the second quarter worth $25,000. Cubist Systematic Strategies LLC acquired a new position in shares of Allakos during the 2nd quarter worth $55,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Allakos in the 2nd quarter valued at about $112,000. RBF Capital LLC increased its holdings in shares of Allakos by 45.9% in the 3rd quarter. RBF Capital LLC now owns 510,529 shares of the company’s stock valued at $333,000 after purchasing an additional 160,529 shares in the last quarter. Finally, GSA Capital Partners LLP lifted its stake in shares of Allakos by 11.9% in the third quarter. GSA Capital Partners LLP now owns 794,896 shares of the company’s stock valued at $519,000 after purchasing an additional 84,750 shares during the period. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

Allakos Stock Performance

ALLK opened at $0.91 on Friday. The company has a market cap of $81.30 million, a price-to-earnings ratio of -0.45 and a beta of 0.86. Allakos Inc. has a one year low of $0.54 and a one year high of $1.69. The business’s fifty day moving average is $1.10 and its two-hundred day moving average is $0.90.

Allakos (NASDAQ:ALLK) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.01. On average, analysts predict that Allakos Inc. will post -1.16 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, JMP Securities restated a “market outperform” rating and set a $3.00 target price on shares of Allakos in a research report on Thursday, September 26th.

Allakos Profile

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.